Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

An international team led by researchers at the University of Toronto has found a compound in ginger, called furanodienone ...

Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...

"This next phase of research is crucial to understanding the full potential of vancomycin in PSC-IBD treatment." ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

An international team led by researchers at the University of Toronto has found a compound in ginger, called furanodienone ...

A handful of biotech stocks made an elite list despite being unprofitable. But many show robust sales growth and constructive ...

The mystery of why people with Inflammatory Bowel Disease (IBD) have a four times higher risk of getting life threatening ...